Adia Nutrition announced that its pivotal clinical study on chronic kidney disease (CKD) has received Institutional Review Board (IRB) approval and has been submitted to ClinicalTrials.gov. The study will evaluate the safety and efficacy of Adia's proprietary AdiaVita stem cell and exosome therapy derived from umbilical cord blood in adults with moderate to advanced CKD. This randomized controlled trial aims to track kidney function and inflammation markers to provide clinical data supporting stem cell therapy in kidney disease management. Recruitment will begin soon, marking a key step in advancing regenerative treatments for CKD.
The global enterprise carbon management software market, valued at $16.7 billion in 2024, is projected to grow to $42.2 billion by 2034 at a CAGR of 9.73%. Growth is driven by increasing corporate net-zero commitments, stricter climate regulations, a...
Celsius co-founders Shlomi Daniel Leon and Hanoch Goldstein will pay a combined $6.5 million to settle Federal Trade Commission charges accusing them of falsely promoting the safety and availability of customer deposits. This follows former CEO Alex ...
Enigmatig Limited has invested in KUNGFULAND, the first scripted feature-length action-comedy co-produced under a treaty between Singapore and Canada using virtual production technology. Filming began in June 2026 in Singapore, blending LED wall tech...
The U.S. Bankruptcy Court for the Central District of California confirmed the Plan of Liquidation for Oceanwide Plaza LLC, enabling the $470 million sale of the stalled Downtown Los Angeles development to KPC Square, a joint venture between KPC Grou...
Escalating conflict between the U.S. and Iran has kept oil prices elevated, raising concerns about a fresh energy shock that could increase global headline inflation by about 0.8 percentage points, according to BlackRock. Regions like Europe and part...
